Meanwhile, an early combined analysis of both lung and melanoma BrM patients from a further phase II study illustrated intracranial response rates to pembrolizumab (anti-PD-1) monotherapy of 33% and 22%, respectively, with nearly identical extracranial response rates (107). This evidence concerns the gene PDCD1 and melanoma.